HomeCompareBMCS vs ORCC

BMCS vs ORCC: Dividend Comparison 2026

BMCS yields 181818.18% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMCS wins by $1.8951031795759825e+29M in total portfolio value
10 years
BMCS
BMCS
● Live price
181818.18%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8951031795759825e+29M
Annual income
$189,305,502,041,192,720,000,000,000,000,000,000.00
Full BMCS calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — BMCS vs ORCC

📍 BMCS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMCSORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMCS + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMCS pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMCS
Annual income on $10K today (after 15% tax)
$15,454,545.45/yr
After 10yr DRIP, annual income (after tax)
$160,909,676,735,013,800,000,000,000,000,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, BMCS beats the other by $160,909,676,735,013,800,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMCS + ORCC for your $10,000?

BMCS: 50%ORCC: 50%
100% ORCC50/50100% BMCS
Portfolio after 10yr
$9.475515897879912e+28M
Annual income
$94,652,751,020,596,360,000,000,000,000,000,000.00/yr
Blended yield
99.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

BMCS
No analyst data
Altman Z
0.3
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMCS buys
0
ORCC buys
0
No recent congressional trades found for BMCS or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMCSORCC
Forward yield181818.18%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1.8951031795759825e+29M$21.4K
Annual income after 10y$189,305,502,041,192,720,000,000,000,000,000,000.00$1.04
Total dividends collected$1.8949690612486723e+29M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BMCS vs ORCC ($10,000, DRIP)

YearBMCS PortfolioBMCS Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$18,192,518$18,181,818.18$11,190$489.61+$18.18MBMCS
2$30,932,835,887$30,913,369,892.64$12,229$256.01+$30932.82MBMCS
3$49,156,619,660,049$49,123,521,525,649.34$13,216$130.74+$49156619.65MBMCS
4$73,009,768,971,452,110$72,957,171,388,415,860.00$14,207$66.02+$73009768971.44MBMCS
5$101,348,671,691,011,770,000$101,270,551,238,212,300,000.00$15,234$33.17+$101348671691011.75MBMCS
6$131,490,628,941,834,950,000,000$131,382,185,863,125,600,000,000.00$16,317$16.62+$131490628941834960.00MBMCS
7$159,445,709,700,484,420,000,000,000$159,305,014,727,516,640,000,000,000.00$17,468$8.32+$159445709700484431872.00MBMCS
8$180,706,560,655,892,340,000,000,000,000$180,535,953,746,512,850,000,000,000,000.00$18,695$4.16+$1.8070656065589233e+23MBMCS
9$191,416,744,304,199,340,000,000,000,000,000$191,223,388,284,297,560,000,000,000,000,000.00$20,006$2.08+$1.9141674430419936e+26MBMCS
10$189,510,317,957,598,240,000,000,000,000,000,000$189,305,502,041,192,720,000,000,000,000,000,000.00$21,407$1.04+$1.8951031795759825e+29MBMCS

BMCS vs ORCC: Complete Analysis 2026

BMCSStock

BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer. In addition, the company develops and sells nutraceutical products, such as BioBody Balance, a liquid vitamin concentrate; and BioBody Energy Spray, a caffeine and alcohol free natural vitamin energy spray. It offers its nutraceutical products through gross retail sales. The company was incorporated in 1997 and is based in Southlake, Texas with laser pain centers in Texas, California, New Mexico, and Florida.

Full BMCS Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this BMCS vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMCS vs SCHDBMCS vs JEPIBMCS vs OBMCS vs KOBMCS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.